[ad_1]
On Friday, the pharmaceutical company Pfizer delivered the documentation to the Institute of Public Health so that allow the use and distribution of your vaccine for covid-19 in the country.
The foregoing, despite the fact that the firm had informed that it would initiate said processing during the next week.
“We are pleased to share that this Friday the 27th we started the process for submitting documentation to the ISP, in parallel to the review being carried out by other regulatory agencies in the world “, they indicated from the firm, according to what was reported by Third.
They also added that as a firm they are making available to “the local authorities the results obtained to date so that they can simultaneously carry out the necessary evaluations in terms of quality, safety and efficacy that allow progress towards a potential authorization for emergency use, as determined country by country ”.
If all goes well, the first doses of the vaccine could begin to arrive in Chile at late December, or the first days of January.
Pfizer and its German partner BioNTech presented the authorization to the Food and Drug Administration (FDA) of the United States on Friday last week for the commercialization of its vaccine against covid-19, becoming the first manufacturers to do so in the United States or Europe.
The announcement was expected for several days, after the publication of the results of the ongoing clinical trial since July with 44,000 volunteers in various countries and according to which the vaccine would have an efficacy of a 95% to prevent virus, without serious side effects.
The United States and Europe could authorize it by December: in the first fortnight the FDA, according to estimates by the US government, and in the second by the European Medicines Agency, according to the president of the European Commission, Ursula von der Leyen.
In addition, another vaccine, that of the American company Moderna, has also shown its effectiveness and competes head-to-head with that of Pfizer / BioNTech.
[ad_2]
